Crowley Elizabeth 4

What Happened

• Elizabeth Crowley, Senior Vice President & Chief Product Development Officer of Celldex Therapeutics (CLDX), was granted a derivative award on June 25, 2026 for 100,000 shares. The Form 4 reports the acquisition price as $0.00, indicating an option/award rather than a cash purchase or sale.

Key Details

• Transaction date: June 25, 2026; Filing date: June 29, 2026 (filed 4 days after the transaction; Form 4s are generally due within 2 business days, so this may be late).
• Transaction type/code: A (Award/Grant) — 100,000 derivative securities acquired at $0.00.
• Shares owned after transaction: Not disclosed in this filing.
• Footnotes: F1 — Option granted under the Celldex 2021 Omnibus Equity Incentive Plan. F2 — Vesting: 25% vests June 25, 2027; remaining 75% vests quarterly in equal amounts over the subsequent 12 quarters.

Context

• This was a grant of options/awards (a derivative security). It does not represent an immediate cash outlay or sale; Crowley will need to meet vesting and any exercise conditions to realize value.
• Such grants are common as long-term incentive compensation for executives and do not by themselves signal a buy or sell decision on the open market.